anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a retrospective review of charts of children less than 12 months of age that were diagnosed with influenza and treated with oseltamivir. The chart review will focus on assessment of neurological and other adverse events that may have been related to the administration of oseltamivir. A control population will consist of children less than 12 months treated with either rimantadine or amantadine. The administration of oseltamivir to children at high risk (i.e. immunocompromised hosts) less than 12 months old with influenza is frequently considered in medical practice despite the findings of neurotoxicity in a juvenile rat study. Since oseltamivir is the only active treatment against H5N1 influenza strains, it is imperative to understand the ramifications of its potential widespread use in very young infants in the event of an outbreak. This study is designed to gather documented evidence by which the circumstances of use and defined outcomes can be described. Patient selection will be made by review of hospital inpatient medical records, emergency room medical records and/or pharmacy records to identify patients less than 1 yr old dosed with oseltamivir suspension. Redacting the charts will be done in a manner that will obscure personal health information (individual identifiers) without obscuring the necessary clinical data. A separate research data collection form will be prepared on which critical information can be transcribed that would subsequently be available for analysis. Critical information to be captured at the time of initiating oseltamivir treatment includes: age, birth history, gender, underlying medical conditions, presenting influenza symptoms, if done, type of flu test and dose regime. Critical endpoints to be collected will include the frequency and severity of adverse events, particularly those relating to central nervous system complications.
FIELD: medicine, gynecology. SUBSTANCE: method involves carrying out two successive treatment courses for 10 days each. Course involves the use of antibiotics, proteolytic enzymes and preparation improving microcirculation. Immunomodulating therapy is carried out between 7-days break and involves the use of preparations of thymus, interferon, blood cytokins. After termination of the second course the immunomodulation therapy is carried out for 30 days. EFFECT: enhanced effectiveness of treatment. 4 ex
The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
PURPOSE: To detect the anti-LSP antibody in the serum of liver disease patients and make it helpful for treatment by measuring anti-LSP antibody by an enzyme immunity method with the hepatocellular membrane conjugated protein (LSP) extracted from animals other than man as an antigen.  
     CONSTITUTION: LSP is collected from the fresh liever of, for example, a pig, and it is concd. to 5mg/ml protein concn. On the other hand, the enzyme mark LSP antibody attaching peroxidase to antihuman LgG-goat IgG is prepd. Said pig LSP soln. is fixed to polystyrene beads to make LSP beads. The enzyme labelling antihuman IgG-goat IgG and the human serum to be examined are added into a test tube contg. one piece of said beads, after whih a buffer contg. H 2 O 2  is added to allow reaction to take place. After prescribed time of reaction, a reaction stopping agent is added and the absorbancy of 418mm wavelength is measured. The amount of the anti-LSP antibody is known by using the calibraction work obtd. by using the serum contg. known LSP antibody. 
     COPYRIGHT: (C)1981,JPO&Japio
PURPOSE: To investigate the incidence of and risk factors for failure of detection of active fellow-eye neovascularization on optical coherence tomography(OCT) crosshair scans in patients with unilateral neovascular age-related macular degeneration(AMD).
METHODS: In this retrospective study, patients who experienced the development of active neovascularization in the fellow eye during the follow-up period were included(n = 75). Cases in which the neovascularization in the fellow eye could be identified solely through crosshair scans were defined as the crosshair scan detection group(n = 63). Cases in which the aforementioned findings could not be identified through crosshair scans but could be identified through raster scans were defined as the raster scan detection group(n = 12). The factors were compared between the two groups. Risk factors related to undetected neovascularization on crosshair scans were additionally identified.
RESULTS: Active fellow-eye neovascularization, was not detected on OCT crosshair scans in 12 cases(16.0%) but was identified on raster scans in all cases. There was a significant difference in the proportion of neovascularization types between the crosshair scan detection group and the raster scan detection group(P = 0.023). Among the 35 fellow-eye neovascularization cases in patients with type 3 macular neovascularization(MNV), 10(28.6%) were not detected on crosshair scans. Multivariate analysis revealed a significantly higher risk for undetectable fellow-eye neovascularization on crosshair scans in patients with type 3 MNV than in those with typical neovascular AMD(P = 0.037,β = 9.600).
CONCLUSIONS: Our findings suggest the need for routine OCT raster scans during fellow-eye examinations in patients with unilateral neovascular AMD, particularly when the first-affected eye is diagnosed with type 3 MNV.
NEW MATERIAL:To polypeptide which is a growth hormone of teleost fish and having the following characteristics. Amino acid composition, shown in Table I; amino acid sequence at the N-terminal, shown in Table II; amino acid sequence at the C-terminal, shown in Table III; molecular weight, 22,000; isoelectric point, 5.6-5.7; solubility, soluble in alkaline aqueous solution and hardly soluble or insoluble in neutral and acidic aqueous solution. USE:Hormone promoting the growth of teleost fish. PREPARATION:The pituitary gland of female dog salmon of 3-4 years old and swimming up a river is ground in the presence of a mixture of concentrated hydrochloric acid and acetone and subjected to the refrigerated centrifugal separation, etc. The supernatant liquid is dialyzed with water and freeze-dried. The obtained powder is dispersed in water, adjusted to 5-7pH, filtered to separate the insoluble components, added with hydrochloric acid, and centrifuged to collect the obtained precipitate. The precipitate is treated by Sephadex column chromatography, and the active fraction is collected and freeze-dried to obtain white powder. The objective growth hormone polypeptide can be produced by purifying the powder. The hormone is useful especially for the pisciculture of herrings.
This proposal seeks to identify the neural circuits underlying the cognitive effects of medication assisted therapy (MAT) for OUD. The study will examine the neurocognitive effects of MAT by comparing two preparations with different pharmacodynamic properties (extended release buprenorphine and naltrexone, XRBUP, XRNTX) in three key domains (incentive salience, executive functioning, and emotion processing) using task functional Magnetic Resonance Imaging (MRI). In the 1st phase of the study, forty treatment-seeking OUD patients will be randomized to XRNTX or XRBUP groups after detoxification. Participants will undergo medication induction followed by monthly injections and urine toxicology monitoring for 120 days. Neuroimaging will follow completion of detoxification (pre-treatment) and 15 days after the second injection (on-treatment). The second study phase will extend the paradigm to an independent sample of 160 additional participants and test the explanatory value of MAT-induced changes in the neuroimaging signal in the classification of OUD treatment outcomes.
The invention relates to a novel derivative of conjugate polyenoic fatty acid polyol ester, macrogol ester and sugar ester and an application thereof. A plurality of conjugate polyenoic fatty acids have biological activities of cancer resistance, blood fat reduction, blood sugar reduction and the like, so that the conjugate polyenoic fatty acids receive much concern. However, the extremely easy oxidation characteristics of the polyenoic fatty acids are extremely unbeneficial to the applications of the polyenoic fatty acids. The novel derivative provided by the invention is an ester derivative which is synthesized by treating a plurality of conjugate polyenoic fatty acids, polylol, polyethyleneglycol and sugar molecules serving as raw materials with a catalytic dehydration method and has high oxidation stability and high anticancer activity. Compared with free conjugate polyenoic fatty acids, the novel ester derivative provided by the invention has the advantages that: the oxidation stability of the novel ester derivative is enhanced greatly, the novel ester derivative can be taken as a food additive and a nutrition enhancer, and the shelf life of a conjugate polyenoic fatty acid product is prolonged. More importantly, high anticancer activity of the derivative is kept while the oxidation stability is enhanced, and the derivative can be taken as a novel anticancer medicament and has a wide application prospect.
The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma. Screening tests will be done to ensure subjects are eligible to participate in this study. If the exams, tests and procedures show that subjects can be in the study, and they choose to take part, then they will be "randomized" into one of the two study groups: Group 1 or Group 2. Subjects in Group 1 will receive Gemcitabine 1000 mg/m2 intravenously (directly into a vein) on Day 1 and Day 8 and Pazopanib 800mg by mouth daily. Subjects in Group 2 will receive Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8 and Docetaxel 100 mg/m2 intravenously on Day 8. Both groups will be in 21 day cycles. Both groups will be asked to complete "quality of life" questionnaires, on their first visit, then at 6 weeks (2nd cycle), 18 weeks (6th cycle) and at the end of study treatment. Subjects will be followed for up to 2 years.
7-Amino-cephalosporanic acid or a derivative thereof of formula <FORM:1027750/C2/1> or a 4-ester thereof, in which R represents an esterified OH group, or a corresponding lactone in which R and the OH of the 4-carboxyl group are replaced by a lactone oxygen atom, are prepared by treating a diester of cephalosporin C or a derivative thereof of formula <FORM:1027750/C2/2> in which R represents an esterified OH and both carboxyl groups are esterified, or a corresponding lactone in which R and the OH group of the 4-carboxyl are replaced by a lactone oxygen atom and the side chain carboxyl is esterified; with an inert solvent until the acyl group attached to the 7-amino group is split off and the resulting ester or lactone is isolated and, if desired, the ester group in the 4-position of the resulting ester is split off. The solvent may be a chlorinated hydrocarbon. The reaction time may be reduced by adding to the solvent an acid, e.g. glacial acetic acid with or without the further addition of an organic base, e.g. pyridine.  The ester group of the 7-aminocephalosporanic acid of Formula I may be removed by (a) trifluoracetic acid and anisole or (b) catalytic hydrogenation. Preferred diesters are the benzhydryl, p-methoxybenzyl, p-nitrobenzyl and benzyl diesters.  The diester of cephalosporin C is prepared by blocking the free amino group of cephalosporin C by an amino-protecting group, e.g. trifluoracetyl, tosyl, carbobenzoxy, trityl, o-nitrophenylsulphenyl or t-butyloxy-carbonyl, then esterifying the carboxylic groups and splitting off the amino-protecting groups.  For cephalosporin C dibenzyl ester, cephalosporin C is treated with t-butyl-oxycarbonylazide followed by phenyldiazomethane to give N-t-butyloxycarbonyl - cephalosporin C dibenzyl ester and the t-butyloxycarbonyl group is removed by treatment with trichloroacetic acid.
OBJECTIVES: Sarcopenia is characterized by the loss of muscle mass. Skeletal muscle can produce and secrete different molecules called myokines. Irisin and myostatin are antagonistic myokines, and to our knowledge, no studies of both myokines have been conducted in patients with disease-related malnutrition (DRM). This study aimed to investigate the role of circulating irisin and myostatin in sarcopenia in patients with DRM.
METHODS: The study included 108 outpatients with DRM according to the Global Leadership Initiative on Malnutrition criteria. Participants had a mean age of 67.4 ± 3.4 y. Anthropometric data, muscle mass by ultrasound at the rectus femoris quadriceps (RFQ) level, impedancemetry (skeletal muscle mass [SMM], appendicular SMM [aSMM], and aSMM index [aSMMI]), dynamometry, biochemical parameters, dietary intake, circulating irisin and myostatin levels were determined in all patients. Confirmed sarcopenia was diagnosed as criteria of probable sarcopenia (low muscle strength) plus abnormal aSMMI.
RESULTS: Of the 108 patients, 44 presented sarcopenia (41%); 64 did not present with the disorder (59%). The following parameters were worse in patients with sarcopenia: Patients without sarcopenia were stronger than those with the disorder (7.9 ±1.3 kg; P = 0.01). Circulating irisin levels were higher in patients without sarcopenia than those with sarcopenia (651.3 ± 221.3 pg/mL; P =0.01). Myostatin levels were similar in both groups. Finally, logistic regression analysis reported a low risk for sarcopenia (odds ratio, 0.39; 95% confidence interval, 0.19-0.92; P = 0.03) in high irisin median levels as a dichotomic parameter after adjusting for body mass index, sex, energy intake, and age.
CONCLUSION: The present study reported that low levels of serum irisin were closely associated with sarcopenia in patients with DRM.
The southern root-knot nematode, Meloidogyne incognita, is a highly serious plant parasitic nematode species that causes significant economic losses in various crops, including cucumber (Cucumis sativus L.). Currently, there are no commercial cultivars available with resistance to M. incognita in cucumber. However, the African horned melon (Cucumis metuliferus Naud.), a semi-wild relative of cucumber, has shown high resistance to M. incognita. In this study, we constructed an ultrahigh-density genetic linkage bin-map using low-coverage sequences from an F2 population generated through the cross between C. metuliferus inbred lines CM3 and CM27. Finally, we identified a QTL (quantitative trait locus, QTL3.1) with a LOD (logarithm of the odds) score of 3.84, explaining 8.4% of the resistance variation. Subsequently, by combining the results of qPCR (quantitative PCR) and VIGS (virus-induced gene silencing), we identified two genes, EVM0025394 and EVM0006042, that are potentially involved in the resistance to M. incognita in CM3. The identification of QTLs and candidate genes in this study serve as a basis for further functional analysis and lay the groundwork for harnessing this resistance trait.
Studies have found a U-shaped relationship between sleep duration and chronic kidney disease (CKD) risk, but limited research evaluated the association of reallocating excessive sleep to other behavior with CKD. We included 104 538 participants from the nationwide cohort of the Risk Evaluation of Cancers in Chinese Diabetic Individuals: A Longitudinal Study, with self-reported time of daily-life behavior. Using isotemporal substitution models, we found that substituting 1 h of sleeping with sitting, walking, or moderate-to-vigorous physical activity was associated with a lower CKD prevalence. Leisure-time physical activity displacement was associated with a greater prevalence reduction than occupational physical activity in working population. In stratified analysis, a lower CKD prevalence related to substitution toward physical activity was found in long sleepers. More pronounced correlations were observed in long sleepers with diabetes than in those with prediabetes, and they benefited from other behavior substitutions toward a more active way. The U-shaped association between sleep duration and CKD prevalence implied the potential effects of insufficient and excessive sleep on the kidneys, in which the pernicious link with oversleep could be reversed by time reallocation to physical activity. The divergence in the predicted effect on CKD following time reallocation to behavior of different domains and intensities and in subpopulations with diverse metabolic statuses underlined the importance of optimizing sleeping patterns and adjusting integral behavioral composition.
Embodiments relate to an aligner breakage solution. A method includes obtaining a digital design of a polymeric aligner for a dental arch of a patient. The polymeric aligner is shaped to apply forces to teeth of the dental arch. The method also includes performing an analysis on the digital design of the polymeric aligner using at least one of a) a trained machine learning model, b) a numerical simulation, c) a geometry evaluator or d) a rules engine. The method may also include determining, based on the analysis, whether the digital design of the polymeric aligner includes probable points of damage, wherein for a probable point of damage there is a threshold probability that breakage, deformation, or warpage will occur. The method may also include, responsive to determining that the digital design of the polymeric aligner comprises probable points of damage, performing corrective actions based on the probable points of damage.
The invention discloses a manufacturing and application method of a bioenzyme-process keratinization mask. The method comprises the following steps: pretreating bioenzyme-process mask raw materials, preparing keratinase, optimizing enzyme action conditions, combining the keratinase with a cotton linter mask, carrying out keratinase low-temperature preservation, and using the mask at room temperature. The keratin degrading bacterium Microbacterium sp. TSMC-99 is fully utilized to ferment and produce the keratinase, and the keratinase adsorbed on the mask catalyzes the degradation of partial keratinized tissues, thereby removing the keratinized scurf on the face, removing dead skin, moisturizing the face, enabling the skin to be clear and bright and performing the function of rejuvenating the skin. The bioenzyme-process keratinization mask is a biological high-tech product which has the advantages of no toxicity, no pollution, no side effect and high safety. The method has the advantages of mild production conditions, environment friendliness and low cost, and is simple to operate and easy for popularization. The technical indexes of the prepared mask satisfy the specifications in Light Industry Standard for masks QB/T 2872-2007.
Lymphocyte antigen 6 complex locus K (LY6K) has been demonstrated to play a significant role in cancers and identified as a therapeutic biomarker for head and neck squamous cell carcinoma. However, the role of LY6K in oral squamous cell carcinoma (OSCC) has not been explored. The current study discovered that LY6K was aberrantly upregulated in OSCC cell lines and tissues and that high LY6K expression significantly correlated with poorer survival of OSCC patients. Through stable knockdown of LY6K, we found that the growth, colony formation, migration, and invasion of OSCC cells were substantially suppressed. In addition, tumor growth and lung metastasis in vivo were effectively inhibited by LY6K depletion. Mechanically, LY6K binds with CAV-1 and activates CAV-1-mediated MAPK/ERK signaling to exert its oncogenic effects on OSCC. In addition, LY6K expression in OSCC was discovered to be regulated by FTO-mediated RNA N6-methyladenosine (m6A) modification in an IGF2BP1-dependent manner. Generally, LY6K expression was upregulated by FTO-mediated demethylation in OSCC, which promoted the tumorigenesis and metastasis of OSCC via activating the CAV-1-mediated ERK1/2 signaling pathway.
Patients in this group will participate in 2 months Pilates exercise program, 2 times per week for 16 sessions, and will follow traditional dietary advice. Warming up and cooling down stretches for 5 minutes will be done before and after exercise .
The present invention provides a porcine antigen that binds to human xenoreactive antibodies. The porcine antigen differs from the known porcine xenoantigens in that the antigen does not include an αGal epitope. The present invention also provides methods to purify the porcine antigen of the invention, as well as agents that bind to the antigen. The antigen may be used to generate antibodies against the antigen. The antigen is useful for detecting the presence of human xenoreactive antibodies against the antigen in blood and blood compositions, and antibodies against the antigen may be used to detect the presence of the antigen in samples. The invention also provides methods and pharmaceutical compositions for reducing a host rejection response to a porcine xenograft. Finally, a method to treat human blood or blood-derived compositions to reduce the level of human xenoantibodies is disclosed.
This study was intended to be divided into two study cocohorts. Cohort one was BRAF V600E mutated NSCLC patients who had not received systemic treatment (first-line). Cohort 2 included patients with BRAF V600E mutated NSCLC who had received systemic therapy (second-line and above); There were 30 patients in cohort 1 and 39 in cohort 2, a total of 69 evaluable cases. A sample size of 73 patients with advanced NSCLC with BRAF V600E mutation (32 /41, respectively) was calculated at a 5% shedding rate. All patients in the first/second line and above were eligible for inclusion. The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1 Efficacy Evaluation Criteria for solid tumors. Subjects were evaluated for tumor imaging every 6 weeks (±7 days), and for complete response (CR) or partial response (PR) at the first imaging assessment, reconfirmation was performed at ≥4 weeks. Safety will be assessed by vital signs, physical examination, ECOG score, clinical laboratory tests (blood routine, blood biochemistry, coagulation function, urine routine, myocardial enzymes), 12-lead electrocardiogram (ECG), echocardiogram (ECHO) examination, and incidence and severity of AE.
<P>PROBLEM TO BE SOLVED: To provide an effective growth-promoting agent.  <P>SOLUTION: This growth-promoting agent which provides a substitute for fetal bovine serum is obtained from a milk product. Furthermore, a milk product extract composition comprises a plurality of cell growth promoting factors extracted from the milk product in a concentrated form and having a basic or a nearly neutral isoelectric point. A pharmaceutically or a veterinary composition comprises a cell culture composition and the milk product extract. A method for preparing the composition and a method for using the composition are provided.  <P>COPYRIGHT: (C)2003,JPO